What does a lesion on your spleen mean?

In the immunocompromised patient, multiple small splenic lesions usually represent disseminated fungal disease and microabscesses. The spleen is a relatively rare site for metastatic disease; patients with metastatic lesions in the spleen usually have disease in other sites as well.

Should I be worried about spleen lesions?

The presence of lesions in other organs in addition to the spleen should raise suspicion for metastases or metastatic primary splenic angiosarcoma. Rarely, patients with benign neoplasms may present with abnormal laboratory values, such as thrombocytopenia or anemia.

What causes lesions on the spleen?

The causes of splenomegaly are myriad and include portal hypertension, liver disease, hematologic malignancies, infection, inflammation, and primary splenic disease. Ultrasound or computerized tomography (CT) imaging studies can reveal a solitary splenic lesion.

What percentage of spleen lesions are cancerous?

In 320 of 379 patients (84.4%), splenic masses were benign. Of 379 masses, 59 (15.6%) were malignant.

Is a lesion on the spleen serious?

Hypodense splenic lesions are frequently encountered on abdominal CT images. Although most hypodense lesions of the spleen can be considered benign, some findings and clinical conditions warrant closer attention to the lesion.

What is the treatment for lesions on the spleen?

Once a diagnosis has been established, treatment is based mainly on surgery: total splenectomy for malignant lesions, or partial splenectomy whenever possible for benign lesions benign that are symptomatic and/or at risk of rupture.

How common are splenic lesions?

World population incidence of focal splenic lesions ranges from 0.103 to 0.20 %; of these lesions true cysts account for 21.35 %, angiomas 14.56 %, calcification and infarctions 9.7 %, pseudocysts, also referred to as false cysts, 8.73 %, lymphomas and abscesses 7.76 %, and metastases 4.85 % [2, 3].

Can spleen lesions cause pain?

Abstract. Hamartomas are benign splenic neoplasms asymptomatic in most of the cases. Symptoms, when present, may either be related to the growth of the mass with abdominal discomfort and pain or be related to a hypersplenism syndrome.

What is the most common malignancy of the spleen?

Although rare, angiosarcoma is the most common primary non-hematopoietic malignant tumor of the spleen. This is a highly aggressive tumor with poor prognosis. Spenomegaly is commonly found and spontaneous splenic rupture has been reported in approximately 25% of patients.

How common are spleen lesions?

Are spleen lesions common?

Splenic lesions are commonly encountered and are often incidental in nature. Benign splenic vascular neoplasms include hemangioma, hamartoma, lymphangioma, extra-medullary hematopoiesis (EMH), and sclerosing angiomatoid nodular transformation (SANT).

What are the etiologies of multifocal splenic lesions?

Etiologies for multifocal splenic lesions include infectious and inflammatory processes, primary vascular and lymphoid neoplasms, metastatic disease, vasc … Lesions in the spleen may be encountered in a variety of clinical settings ranging from asymptomatic patients to patients who are critically ill.

What are the etiologies of lesions in the spleen?

Lesions in the spleen may be encountered in a variety of clinical settings ranging from asymptomatic patients to patients who are critically ill. Etiologies for multifocal splenic lesions include infectious and inflammatory processes, primary vascular and lymphoid neoplasms, metastatic disease, vasc …

What causes nodular lesions in the splenic tract?

Multiple, small, nodular splenic lesions are encountered in a wide variety of diseases ( Box 105-4 ). These consist of bacterial, fungal, and protozoal infections; granulomatous diseases, including mycobacterial infections; and sarcoidosis and malignant neoplasms, such as lymphoma and metastases.

What causes focal splenic lesions in Type I Gaucher disease?

Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. (2010) Journal of Inherited Metabolic Disease. 33 (6): 769. doi:10.1007/s10545-010-9175-6 – Pubmed 9. R.K. Kaza, S. Azar, M.M. Al-Hawary, I.R. Francis.